RxDoctor Payments Data

Duane Schuil, MD

Interventional Cardiology · Petoskey, MINPI 1245253392

Payments from drug & device makers

$584in general payments, 2019–2025

Across 28 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$206
  • Shockwave Medical, Inc$133
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$62
  • Novartis$55
  • E.r. Squibb & Sons, L.L.C.$32
  • Boston Scientific$30
  • plus $66 from 5 others

What the payments were for

  • Food & beverage$584100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$584 in reported general payments places this provider in the 5th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$32,257
Medicare patients
224
Services billed
447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$75,182
EntrestoSacubitril/Valsartan20$26,285
Repatha SureclickEvolocumab12$17,791
XareltoRivaroxaban16$17,136
Metoprolol Succinate57$1,255
Atorvastatin Calcium84$989
Bumetanide13$628
Rosuvastatin Calcium26$538
Potassium Chloride34$481
Lisinopril39$459
Ezetimibe14$430
Isosorbide Mononitrate ErIsosorbide Mononitrate11$416
Losartan Potassium18$392
Amlodipine Besylate27$388
ClopidogrelClopidogrel Bisulfate34$388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$55$26,28520 claims
Johnson & JohnsonXarelto$206$17,13616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Petoskey

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →